Empyrean Neuroscience

New York, United States

Empyrean is using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare.

$22.0M raised

Oct 2022

Series A

Biotechnology Life Science Neuroscience

Top Investors

Spore Partners

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Empyrean Neuroscience

How much funding has Empyrean Neuroscience raised?

Empyrean Neuroscience has raised $22.0M in total funding. The most recent round was Series A. The last funding was announced in October 2022.

Who are Empyrean Neuroscience's investors?

Empyrean Neuroscience's investors include Spore Partners.

Where is Empyrean Neuroscience headquartered?

Empyrean Neuroscience is headquartered in New York, United States.

What does Empyrean Neuroscience do?

Empyrean is using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare.

What stage is Empyrean Neuroscience at?

Empyrean Neuroscience is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 18, 2022.

MLA

"Empyrean Neuroscience — Funding & Investors." VCBacked, October 18, 2022, https://www.vcbacked.co/company/empyrean-neuroscience. Accessed July 3, 2026.

APA

VCBacked. (2022). Empyrean Neuroscience — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/empyrean-neuroscience

Wikipedia (cite web)

{{cite web |title=Empyrean Neuroscience — Funding & Investors |url=https://www.vcbacked.co/company/empyrean-neuroscience |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 18, 2022.